natgillin/translations-raw huggingface dataset:
The results summarized in Table 3 show that the recovery and purification factor were optimal using a solution of 35% PG in the elution step (Table 3). 
Sumarni rezultati prikazani u Tablici 3 pokazuju da su prinos i faktor pročišćavanja optimalni ako se koristi 35%-tni PG u koraku euacije (Tablic).
The DIOFAN A036 is the primary constituent of the coating for controlling the gas exchange of the post harvest produce. 
DIOFAN A036 je primarni sastojak ovojnice za kontrolu razmjene plinova ubranog proizvoda.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NTRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Rg je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila,
The amount of carrageenan is typically in the range of between 5% and 25%, more preferably between 10% and 20%, by weight of the mixture. The composition comprising the mixture can be used to form a core. 
Sastav u skladu spatentnim zahtjevom 1 ili 2, pri čemu je količina karagenana sadržana između 5% 1 25%, poželjnije između 10% 120%, u odnosu na masu sastava.
The solid formulation according to the invention may also comprise one or several flow regulators selected from the group consisting of silica, preferably colloidal anhydrous silica, calcium silicate, magnesium silicate, talc, and the like. 
Čvrsta formulacija prema patentnom zahtjevu 2 ili 4, naznačena time, da je dezintegrator/nosač odabran iz skupine koja se sastoji od laktoze, škroba, mikrokristalne celuloze i metilceluloze, a poželjno je naznačena time, da nosači su škrob 1 laktoza.
a mouse k light chain constant region gene, wherein the plurality of contiguous unrearranged functional hVλ gene segments and the plurality of contiguous unrearranged functional hJλ gene segments are operably linked to the mouse k light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable domain encoded by the rearranged human λ light chain variable region and a constant domain encoded by the mouse k light chain constant region gene, allowing the genetically modified mouse to develop an immune response to the antigen; and 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K. Genetski modificirani miš prema zahtjevu 4, naznačen time, što miš dodatno sadrži sekvencu humane Vx-JK međugenske regije koja se nalazi između humanih V2 genskih segmenata i humanih JA genskih segmenata.
R2' is hydrogen; (C1-C4)alkyl optionally substituted with a methoxy; or a phenyl group, the phenyl group being optionally substituted with a methoxy group; 
’ je vodik; (C1-C4)alkil koji može biti supstituiran s metoksi; ili fenilna skupina koja može biti supstituirana s metoksi skupinom;
The solid oral extended release pharmaceutical dosage form of any one of items 84 and 85, wherein the extended release matrix formulation resists a work of at least about 0.06 J without cracking. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
fractions A and B of the virgin Ziegler-Natta catalyzed polyethylene resin are prepared in at least 2 reactors preferably operated in series. 
- Frakcije A 1 B neobrađene Ziegler-Natta katalizirane polietilenske smole su pripravljene u minimalno 2 reaktora i to poželjno u serijama.
a primer pair having the sequence as set in SEQ ID NO: 5 and 6, and 
par početnica koje imaju sekvencu kako je navedeno u SEQ ID NO: 5 i 6, i
A fuel gas supply system of a vessel except an LNG carrier, comprising: 
Sustav dobave pogonskog plina za plovilo osim za LNG tanker, koji sadrži: spremnik LNG (1);
a lipid, a fatty acid, a sterol), a protein, a peptide, an antibody or fragment thereof, a polymer, a reporter group, a dye, a receptor ligand, a small molecule drug, a prodrug, and a vitamin. 
lipida, masne kiseline, sterola), proteina, peptida, protutijela ili njegova fragmenta, polimera, reporterske skupine, boje, liganda receptora, lijeka male molekule, predlijeka 1 vitamina.
A humanized anti-human a9 integrin antibody comprising a heavy chain variable region and a light chain variable region selected from the following: 
Humanizirano anti-humani-alfa9-integrin-protutijelo, naznačeno time, da obuhvaća varijabilno područje jakog lanca i varijabilno područje slabog lanca odabrane od sljedećih:
Additional specific embodiments of the disclosure include: 
Datum podnošenja europske prijave patenta:
An antibody that binds CD19, said antibody comprising a light chain comprising SEQ ID NO: 106, and a heavy chain comprising SEQ ID NO: 87. 
Antitijelo prema zahtjevu 1, naznačeno time da navedeni teški lanac sadrži SEQ ID NO: 40 i navedena sekvenca lakog lanca sadrži SEQ ID NO: 58.
passing a second gas containing at least about 50% methane by volume through said first condensate and a metallic catalyst grid, both said first condensate and said metallic catalyst grid contained in a second reaction vessel, with said first condensate at a temperature of about 80°C or above but below the boiling temperature of said first condensate, said metallic catalyst grid comprising windings of a transition metal supported on an iron frame; 
(b) propuštanje drugog plina koji sadrži najmanje otprilike 50 % metana, volumno, kroz navedeni prvi kondenzat i rešetku metalnog katalizatora, gdje se i navedeni prvi kondenzat i navedena rešetka metalnog katalizatora nalaze u drugoj reakcijskoj posudi, gdje je navedeni prvi kondenzat na temperaturi od otprilike 80 *€ ili iznad, no ispod temperature vrenja od navedenog prvog kondenzata, gdje navedena rešetka metalnog katalizatora sadrži namotaje od prijelaznog metala koje nosi željezni okvir;
A dietary supplement stimulating the male sexual function comprising: 
Nadomjestak prehrani za stimulaciju muške seksualne funkcije, naznačen time da sadrži:
The compound of claim 6, wherein the salt is a hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic, or trifluoroacetic acid salt. 
Farmaceutski prihvatljiva sol prema patentnom zahtjevu 19, naznačena time, što sol predstavlja sol klorovodične, bromovodične, jodovodične, perklorne, sumporne, dušične, fosforne, octene, propionske, glikolne, mliječne, jantarne, maleinske, fumarne, jabučne, vinske, limunske, benzojeve, bademove, = metansulfonske, hidroksietansulfonske, benzensulfonske, oksalne, 2-naftalensulfonske, p-toluensulfonske, cikloheksansulfaminske, salicilne, saharinske ili soli trifluoroctene kiseline.
A method as in claim 7, wherein said hydrogenation catalyst is Pt/C and the reaction is performed in a solvent mixture of ethyl acetate and acetic acid. 
Postupak prema patentnom zahtjevu 7, naznačen time da je navedeni katalizator hidrogenizacije PI/C 1 da je reakcija izvedena u smjesi otapala etil acetata 1 octene kiseline.
Alternatively the primed cells may be contacted with T cells in vitro in order to generate T cells (particularly CTLs, but also helper T cells or Tregs) specific for the antigen. Thus, following said contacting step, the method may comprise contacting said population of human dendritic cells expressing CLEC9a with a population of cells comprising one or more T cells. 
Postupak prema zahtjevu 23, naznačen time, da obuhvaća, nakon navedene faze stavljanja u doticaj, stavljanje u doticaj navedenih stanica koje predstavljaju antigen in vitro, s populacijom autolognih stanica koje sadrže jednu ili više T-stanica, te opcijski povećanje T-stanica u populaciji.
(a1) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 1; 
(al) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 1;
The lighting module of claim 1, wherein said switching device is a MOSFET. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni preklopni sklop MOSFET.
receiving the frame of the encoded digital audio signal; and 
prijem okvira kodiranog digitalnog audio signala; i
the lysine at position 11 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. 
tirozin na položaju 11 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V ili W.
A compound of formula (I) according to claim 1 wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, and R3 represents a methyl group; or a pharmaceutically acceptable salt thereof. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što R1 predstavlja atom vodika, R2 predstavlja atom vodika, a R3 predstavlja metilnu skupinu; ili njegova farmaceutski prihvatljiva sol.
The fixture may engage the CD(s) in the centre hole or the outer edge of the disc. 
Sredstvo za pričvršćivanje može zahvatiti CD (CD-ove) u središnjoj rupi ili na vanjskom rubu diska.
A second nucleic acid molecule encoding a 2nd human IgG CH3 domain-comprising polypeptide chain comprising an aspartic acid (D) residue at amino acid position 351 according to the EU numbering system, A third nucleic acid molecule encoding a 3rd CH3 domain-comprising polypeptide chain, and 
druge molekule nukleinske kiseline koja kodira drugi polipeptidni lanac koji sadrži CH3 domenu humanog IgG, koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavu numeracije, c. = treće molekule nukleinske kiseline koja kodira treći polipeptidni lanac koji sadrži CH3 domenu i d.
A vector according to claim 14, wherein the vector comprises (i) the sequence given in SEQ ID NO: 30, 32, 34 or 36 and the sequence given in SEQ ID NO: 21 or 24 or (ii) the sequence given in SEQ ID NO: 38 and the sequence given in SEQ ID NO: 22, or (iii) the sequence given in SEQ ID NO: 74 and the sequence given in SEQ ID NO: 22 or (iv) the sequence given in SEQ ID NO: 41 and the sequence given in SEQ ID NO: 43. 
Vektor prema patentnom zahtjevu 14, naznačen time, što se vektor sastoji od (i) sekvence navedene u SEQ ID NO: 30, 32, 34 ili 36 i sekvence navedene u SEQ ID NO: 21 ili 24 ili (ii) sekvence navedene u SEQ ID NO: 38 i sekvence navedene u SEQ ID NO: 22 ili (iii) sekvence navedene u SEQ ID NO: 74 i sekvence navedene u SEQ ID NO: 22 ili (iv) sekvence navedene u SEQ ID NO: 41 i sekvence navedene u SEQ ID NO: 43.
In one embodiment the process is a process for preserving the Bordetella species in a bvg+ genotype in industrial culture. 
(i) očuvanju vrste iz roda Bordetella genotipa bvg+ u industrijskoj kulturi,
The method of claim 45, wherein the sleep disorder is a sleep-wake transition disorder, insomnia, restless legs syndrome, jet-lag, disturbed sleep, or a sleep disorder secondary to neurological disorders. 
Spoj za uporabu prema zahtjevu 25, naznačen time da je poremećaj spavanja poremećaj prelaska iz sna u budnost, nesanica, sindrom nemirnih nogu, jet-lag, poremećaj spavanja, ili sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
A method for treating acne comprising applying once a day for up to 12 weeks to the skin of a patient in need thereof an aqueous formulation according to claim 1 . 
Vodena formulacija sukladno patentnom zahtjevu 1 pri čemu je omjer vode u odnosu propilen glikolu u toj formulaciji najmanje 12:1 (w/w).
The topical gel composition of claim 12, comprising greater than 0.3 (w/w) phenoxyethanol as the second preservative. 
Kompozicija topičkog gela prema zahtjevu 9, pri čemu ta kompozicija sadrži više od 0,3 (w/w) fenoksietanola.
The crystalline complex according to any one of claims 1 to 6, wherein the X-ray powder diffraction pattern comprises peaks at 4.99, 15.12, 17.61, 17.77, 18.17, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees 2 Θ (±0.1 degrees 2 Θ), wherein said X-ray powder diffraction pattern is made using CuKa1 radiation. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da uzorak difrakcije praha X-zraka obuhvaća vršne vrijednosti na 4,99, 15,12, 17,61, 17,77, 18,17, 20,28, 21,14, 21,64, 23,23 1 27,66 stupnjeva 20 (+ 0,1 stupanj 20), pri čemu se navedeni uzorak difrakcije praha X-zraka dobiva uporabom CuK.,-radijacije.
Process according claims 1 or 2, characterized in that the water outlet (3) is a tube with holes. 
Uređaj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time da odvod vode (3) je cijev sa rupama.
The use as claimed in claim 5, wherein the crop plants are crops of wheat, barley, rye, triticale, durum, rice, corn, sugarcane, sorghum, soybean, pulse crops, peanut, sunflower, sugarbeet, potato, cotton, brassica crops, turf, grapes, pomefruit, stonefruit, citrus, coffee, pistachio, garden ornamentals, bulb ornamentals, conifers and deciduous trees. 
Uporaba prema patentnom zahtjevu 5, gdje su usjevi pšenica, ječam, raž, hibrid pšenice 1 raži, durum pšenica, riža, kukuruz, šećerna trska, sirak, soja, mahunarke, kikiriki, suncokret, šećerna repa, krumpir, pamuk, kupusnjače, travnjaci, grožđe, jabuke i srodno voće, koštuničavo voće, citrusi, kava, pistacija, ukrasne vrtne biljke, gomoljaste ukrasne biljke, crnogorično i bjelogorično drveće.
An agent for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin-C, wherein the agent is an antibody or antigen-binding fragment thereof having specificity for the FBG domain of tenascin-C. 
Sredstvo za modulaciju kroničnog upalnog odgovora pri čemu sredstvo modulira biološku aktivnost za tenasein-C, naznačeno time da je sredstvo antitijelo il i njegov fragment koji veže antigen koje ima specifičnost za FBG domenu za tenascin-C.
is selected from the group consisting of hydrogen and C1-6 alkyl; 
je odabran iz skupine koju čine vodik i C1-6alkil;
the at least one active immunogenic component comprises live attenuated canine adenovirus type 2 (CAV2) and live attenuated canine parvovirus (CPV) or 
najmanje jedna aktivna imunogena komponenta sadrži živi atenuirani adenovirus pasa tipa 2 (CAV2) i živi atenuirani parvovirus pasa (CPV) ili
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od [image]
To a stirred solution of zinc iodide (2.05 g, 6.26 mmol) and Intermediate 57 (9.3 g, 31.3 mmol) in dichloromethane (10 mL) was added trimethylsilylcyanide (4.29 mL, 31.3 mmol) with water bath cooling. 
U miješanu otopinu cink jodida (2.05 g, 6.26 mmol) i Intermedijera 57 (9.3 g, 31.3 mmol) u diklorometanu (10 mL) dodan je trimetilsililcijanid (4.29 mL, 31.3 mmol) uz hladenje vodenom kupelji.
Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, is hydroxyl, or Cyc1, in which Cyc1 is a ring system of formula Ia 
Ahl je heteroaril-arilni radikal ili aril-heteroarilni radikal, kojeg čine heteroarilna skupina, koju se bira iz skupine koju čine monociklički 5- ili 6-eročlani heteroarilni radikali, koji sadrže jedan ili dva heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, i arilna skupina, koju se bira iz skupine koju čine fenil i naftil, gdje su navedene heteroarilne i arilne skupine vezane zajedno jednostrukom vezom, R7 je hidroksil ili Cyc1, gdje Cyc1 je sustav prstena formule Ia
represents any of the following (1) to (7): 
R* predstavlja bilo što od sljedećeg (1) do (7):
By sugar is understood sucrose but also other commonly used calorie rich sweetening additives such as glucose, fructose and high fructose corn syrups. 
Pod šećerom se podrazumijeva saharoza, ali i drugi kalorijama bogati aditivi-zaslađivači poput glukoze, fruktoze i kukuruznih sirupa bogatih fruktozom.
a substitution mutation at 13,397,560 bp; 
mutacije supstitucije na 13,397,560 bp;
Example 1 Ingredient 
Primjer 1 Prašak za inhaliranje
The method of claim 1, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(iv) signalni region 4-IBB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18;
A pharmaceutical composition for use according to claim 6, wherein the pharmaceutical composition is for administration by dry powder inhaler (DPI) or metered-dose inhaler (MDI). 
Farmaceutski pripravak prema zahtjevu 6 namijenjen za primjenu pomoću inhalatora za suhi prašak (DPI) ili inhalatora s odmjerenom dozom (MDI).
The method of claim 3, wherein the fusion protein comprises a formula selected from the group consisting of: 
Fc regiju imunoglobulina. Fuzijski protein prema zahtjevu 1, koji sadrži formulu odabranu od skupine koja se sastoji od:
The residue was triturated with ethyl acetate and the resulting solid collected, washed with ethyl acetate, and dried to give the title compound (1.23 g), m.p. 126-129°. Example 20 
Ostatak se isitni s etilacetatom i preostala čvrsta supstanca se sakupi, ispere s etilacetatom i suši tako da se dobi ja naslovni spoj (1,23 g), t.t. 126-129".
In accordance with the above, presented herein are methods of preparing an immobilized library of tagged DNA fragments. 
PATENTNI ZAHTJEVI Postupak priprave imobilizirane biblioteke obilježenih fragmenata DNA, naznačen time što se sastoji u:
By this means a liquid-tight barrier is obtained and liquid is prevented from leaking outwards from the central part 30 along the contact plane 36. 
Na taj način postiže se nepropusna barijera i tekućina ne može istjecati iz središnjeg dijela 30 uzduž dodirne ravnine 36.
a pierceable cover (7) closing the extremity of the discharge outlet (6) and of the opened extremity (4) of the vessel (2). 
- pokrov kojeg se može probušiti (7), koji zatvara kraj izlaza za pražnjenje (6) i otvorenog kraja (4) posude (2).
Pharmaceutical formulation according to any one of Claims 8 to 10, in which the pharmaceutical formulation is chosen from the group comprising tablets, capsules, coated tablets, granules, solutions and syrups for oral administration, antiseptic plasters, solutions, pastes, creams and ointments for transdermal administration, suppositories for rectal administration, sterile solutions for injection or aerosol administration, in either immediate-release or sustained-release form. 
11.Farmaceutska formulacija prema bilo kojem od zahtjeva 8 do 10, naznačena time, da je farmaceutska formulacija odabrana iz skupine koju čine tablete, kapsule, obložene tablete, granule, otopine i sirupi za oralnu primjenu, antiseptički flasteri, otopine, kaše, kreme 1 masti za transdermalnu primjenu, supozitoriji za rektalnu primjenu, sterilne otopine za injekcijsku ili aerosolnu primjenu, u obliku trenutnog otpuštanja ili u obliku odgođenog otpuštanja.
The capsule according to claim 1 or 2, wherein the valve means (15) is placed downstream of the lower face. 
Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što ventil (15) se nalazi nizvodno od površine (4) odjeljka.
The immunogenic composition of any preceding claim wherein each N . meningitidis capsular polysaccharide is conjugated to a carrier protein independently selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
The reaction mixture is stirred at 0°C for 15 minutes, then allowed to warm to room temperature. 
Reakcijsku smjesu se miješa 15 minuta pri 0%C i zatim se pusti zagrijati na sobnu temperaturu.
The solid pharmaceutical composition according to claim 1 wherein the compound of Formula (I) is in the form of Formula (II): 
Jedinični oblik doziranja, formulacija vlažne granulacije, formulacija za sabijanje valjkom ili formulacija za izravnu kompresiju prema zahtjevu 9 naznačen time što je spoj s Formulom (I) u obliku Formula (II): of"
a C3-8 cyclcalkyl-C1-6 alkyl group (wherein C3-8 cycloalkyl is optionally substituted by the same or different 1 to 5 substituents selected from the following group B); 
Cagcikloalkil-Cig4 alkil skupina (gdje Csa cikloalkil je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B);
The condensation of the substituted tetralone with the appropriate secondary amine NHRlR2 in the presence of an acid catalyst, e.g. TiCl4, yields a 3,4-dihydro-1-dialkylamine compound, which is then reduced to the 1,2,3,4-tetrahydro-1-dialkylamine (mixture of cis- and trans-racemates), e.g. with sodium borohydride in the presence of acetic acid. 
kondenzacija supstituiranog tetralona formule (II) sa sekundarnim aminom (R,; i Rx oba alkil) u prisustvu kiselog katalizatora, npr., TiCL, daje 3,4-dihidro-1-dialkilaminski intermedijer (IV), koje se tada reducira u 1,2,3,4-tetramro-1-dialkilamin (smjesa cis- i trans-recemata), npr., s natrij-borohidridom u prisustvu octene kiseline.
According to a preferred embodiment, the extension of the actuation element, preferentially at least of the part of the actuation element disposed on the side of the zone facing the flow upstream, is previously defined as a function at least of the type of aromatic substance and/or of the measured dimension of the grain and/or of the global volume of the capsule. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time, da je produžetak elementa za pokretanje (5, 5e, 5s), poželjno najmanje produžetak dijela elementa (5e) na strani zone (2) okrenute prema protoku uzvodno, prethodno definiran barem kao funkcija vrste aromatske tvari ili prosječne veličine zrna ili unutarnjeg volumena kapsule (1, 1').
The process of claim 8, wherein the solution of hydrobromic acid in acetic acid comprises less than 30 ppm of metal ion impurities. 
Postupak prema patentnom zahtjevu 8, naznačen time, da otopina bromovodične kiseline u octenoj kiselini sadrži manje od 30 ppm nečistoća metalnim ionima.
The mixture was poured into a saturated aqueous solution of ammonium chloride and the product was extracted into ethyl acetate. 
Smjesu se izlije u zasićenu vodenu otopinu amonijevog klorida, a produkt ekstrahira u etilacetat.
The assembly 212 is fitted on a last, which is inserted in the mold, placing the inshoe 227 in contact with the breathable element 221. 
Sklop 212 se pričvršćuje na kalup, koji se umeće u kalup za prešanje, tako da unutarnja cipela 227 dolazi u kontakt s prozračnim elementom 221.